Xu-Shan Sun

668 total citations
13 papers, 193 citations indexed

About

Xu-Shan Sun is a scholar working on Pulmonary and Respiratory Medicine, Otorhinolaryngology and Oncology. According to data from OpenAlex, Xu-Shan Sun has authored 13 papers receiving a total of 193 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pulmonary and Respiratory Medicine, 8 papers in Otorhinolaryngology and 5 papers in Oncology. Recurrent topics in Xu-Shan Sun's work include Head and Neck Cancer Studies (8 papers), Lung Cancer Treatments and Mutations (5 papers) and Lung Cancer Diagnosis and Treatment (4 papers). Xu-Shan Sun is often cited by papers focused on Head and Neck Cancer Studies (8 papers), Lung Cancer Treatments and Mutations (5 papers) and Lung Cancer Diagnosis and Treatment (4 papers). Xu-Shan Sun collaborates with scholars based in France, Switzerland and Luxembourg. Xu-Shan Sun's co-authors include Rodryg Ramlau, Maciej Krzakowski, Jean Bourhis, Christian Sire, Juliette Thariat, Yungan Tao, Esma Saâda, Olfred Hansen, Joachim von Pawel and Laurent Martin and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Radiation Oncology*Biology*Physics and European Journal of Cancer.

In The Last Decade

Xu-Shan Sun

11 papers receiving 185 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xu-Shan Sun France 7 124 80 47 36 36 13 193
Grégoire Marret France 8 119 1.0× 74 0.9× 22 0.5× 27 0.8× 96 2.7× 24 231
Antonino Scimone Italy 9 221 1.8× 165 2.1× 29 0.6× 45 1.3× 72 2.0× 22 327
Juergen Krauss Germany 7 116 0.9× 47 0.6× 13 0.3× 21 0.6× 53 1.5× 14 167
S.-H.I. Ou United States 6 128 1.0× 129 1.6× 87 1.9× 62 1.7× 113 3.1× 16 315
Justin Bishop United States 7 87 0.7× 72 0.9× 49 1.0× 13 0.4× 167 4.6× 9 258
Qinqin Liu China 5 98 0.8× 38 0.5× 105 2.2× 84 2.3× 47 1.3× 15 218
Rachel Galot Belgium 7 92 0.7× 86 1.1× 50 1.1× 14 0.4× 90 2.5× 26 221
Zhen‐Chong Yang China 7 87 0.7× 94 1.2× 100 2.1× 51 1.4× 81 2.3× 16 229
Mingqiu Chen China 11 107 0.9× 106 1.3× 15 0.3× 130 3.6× 147 4.1× 27 358
Shanghua Jing China 10 57 0.5× 44 0.6× 10 0.2× 25 0.7× 128 3.6× 23 214

Countries citing papers authored by Xu-Shan Sun

Since Specialization
Citations

This map shows the geographic impact of Xu-Shan Sun's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xu-Shan Sun with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xu-Shan Sun more than expected).

Fields of papers citing papers by Xu-Shan Sun

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xu-Shan Sun. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xu-Shan Sun. The network helps show where Xu-Shan Sun may publish in the future.

Co-authorship network of co-authors of Xu-Shan Sun

This figure shows the co-authorship network connecting the top 25 collaborators of Xu-Shan Sun. A scholar is included among the top collaborators of Xu-Shan Sun based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xu-Shan Sun. Xu-Shan Sun is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
2.
Biau, J., Xu-Shan Sun, X. Liem, et al.. (2025). 2449 Postoperative SBRT for Early-Stage Oropharyngeal and Oral Cavity Cancers with High-Risk Margins: the STEREOPOSTOP GORTEC 2017-03 phase 2 trial. Radiotherapy and Oncology. 206. S1028–S1029. 1 indexed citations
3.
4.
Borel, Christian, Xu-Shan Sun, Alexandre Coutté, et al.. (2024). Standard versus fractionated high-dose cisplatin plus radiation for locally advanced head and neck cancer: Results of the CisFRad (GORTEC 2015-02) randomized phase II trial. Radiotherapy and Oncology. 197. 110329–110329. 2 indexed citations
5.
6.
Thariat, Juliette, M. Bosset, Déwi Vernerey, et al.. (2024). Survival Without Quality of Life Deterioration in the GORTEC 2014-04 “OMET” Randomized Phase 2 Trial in Patients with Head and Neck Cancer with Oligometastases using Stereotactic Ablative Radiation Therapy (SABR) alone or Chemotherapy and SABR. International Journal of Radiation Oncology*Biology*Physics. 121(5). 1194–1206. 6 indexed citations
7.
8.
Boustani, Jihane, Elodie Lauret Marie Joseph, É. Martin, et al.. (2021). Cisplatin-based chemoradiation decreases telomerase-specific CD4 TH1 response but increases immune suppressive cells in peripheral blood. BMC Immunology. 22(1). 38–38. 8 indexed citations
9.
10.
11.
Souquet, Pierre-Jean, Maciej Krzakowski, Rodryg Ramlau, et al.. (2010). Phase I/II and Pharmacokinetic Study of Intravenous Vinflunine in Combination With Cisplatin for the Treatment of Chemonaive Patients With Advanced Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 11(2). 105–113. 18 indexed citations
12.
Krzakowski, Maciej, Rodryg Ramlau, Jacek Jassem, et al.. (2010). Phase III Trial Comparing Vinflunine With Docetaxel in Second-Line Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy. Journal of Clinical Oncology. 28(13). 2167–2173. 58 indexed citations
13.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Grégoire Marret Breakdown of academic impact, for papers by Antonino Scimone Breakdown of academic impact, for papers by Juergen Krauss Breakdown of academic impact, for papers by S.-H.I. Ou Breakdown of academic impact, for papers by Justin Bishop Breakdown of academic impact, for papers by Qinqin Liu Breakdown of academic impact, for papers by Rachel Galot Breakdown of academic impact, for papers by Zhen‐Chong Yang Breakdown of academic impact, for papers by Mingqiu Chen Breakdown of academic impact, for papers by Shanghua Jing
Rankless by CCL
2026